Difference between revisions of "Prazosin"

From Dog
(Created page with "__NOTOC__ Prazosin is an orally-active α-1-adrenergic blocker which acts as a sympatholytic drug on vascular smooth muscle. Recommended dose rate in dogs is 20-50 μg/kg.")
 
 
(5 intermediate revisions by the same user not shown)
Line 1: Line 1:
 
__NOTOC__
 
__NOTOC__
Prazosin is an orally-active α-1-adrenergic blocker which acts as a sympatholytic drug on vascular smooth muscle.
+
[[File:prazosin.jpg|right|200px]]
 +
Prazosin is an orally-active uroselective α-1-adrenergic antagonist which acts as a sympatholytic drug on vascular smooth muscle. It has very little α-2 antagonist activity<ref>Fischer JR ''et al'' (2003) Urethral pressure profile and hemodynamic effects of phenoxybenzamine and prazosin in non-sedated male beagle dogs. ''Can J Vet Res'' '''67(1)''':30-38</ref>.
 +
 
 +
Traditionally, the drug of choice for the treatment of functional urethral obstruction in dogs has been [[phenoxybenzamine]], another α-adrenergic antagonist, but has been replaced by prazosin as a more selective α-1 antagonist.
 +
 
 +
This drug reduces intraurethral intraluminal pressure and is commonly used in cases of [[prostatic hyperplasia]]<ref>Breslin D ''et al'' (1993) Medical management of benign prostatic hyperplasia: A canine model comparing the in vivo efficacy of alpha-1 adrenergic antagonists in the prostate. ''J Urol'' '''14''':395–399</ref>, acute [[urolithiasis]]<ref>Poirier M ''et al'' (1988) Effects of five alpha-blockers on the hypogastric nerve stimulation of the canine lower urinary tract. ''J Urol'' '''140''':165–167</ref> and [[ureterolithiasis]]<ref>Noguchi Y ''et al'' (2008) In vivo study on the effects of alpha1-adrenoceptor antagonists on intraurethral pressure in the prostatic urethra and intraluminal pressure in the vas deferens in male dogs. ''Eur J Pharmacol'' '''580(1-2)''':256-261</ref>.
  
 
Recommended dose rate in dogs is 20-50 μg/kg.
 
Recommended dose rate in dogs is 20-50 μg/kg.
 +
 +
==References==
 +
<References/>

Latest revision as of 23:58, 18 March 2013

Prazosin.jpg

Prazosin is an orally-active uroselective α-1-adrenergic antagonist which acts as a sympatholytic drug on vascular smooth muscle. It has very little α-2 antagonist activity[1].

Traditionally, the drug of choice for the treatment of functional urethral obstruction in dogs has been phenoxybenzamine, another α-adrenergic antagonist, but has been replaced by prazosin as a more selective α-1 antagonist.

This drug reduces intraurethral intraluminal pressure and is commonly used in cases of prostatic hyperplasia[2], acute urolithiasis[3] and ureterolithiasis[4].

Recommended dose rate in dogs is 20-50 μg/kg.

References

  1. Fischer JR et al (2003) Urethral pressure profile and hemodynamic effects of phenoxybenzamine and prazosin in non-sedated male beagle dogs. Can J Vet Res 67(1):30-38
  2. Breslin D et al (1993) Medical management of benign prostatic hyperplasia: A canine model comparing the in vivo efficacy of alpha-1 adrenergic antagonists in the prostate. J Urol 14:395–399
  3. Poirier M et al (1988) Effects of five alpha-blockers on the hypogastric nerve stimulation of the canine lower urinary tract. J Urol 140:165–167
  4. Noguchi Y et al (2008) In vivo study on the effects of alpha1-adrenoceptor antagonists on intraurethral pressure in the prostatic urethra and intraluminal pressure in the vas deferens in male dogs. Eur J Pharmacol 580(1-2):256-261